News & Stories
The House of Representatives has overwhelmingly approved the ACT for ALS Reauthorization Act, bringing the ALS community one step closer to extending programs that are helping accelerate research, strengthen collaboration, and expand access to investigational therapies for people living with ALS.
Originally enacted in 2021, ACT for ALS established innovative programs that have helped advance ALS research, improve data sharing, strengthen public-private partnerships, and expand opportunities for people living with ALS to access investigational therapies outside of traditional clinical trials. Because the current authorization expires on September 30, congressional action this year is essential to ensure these efforts continue without interruption.
Today’s vote represents another important bipartisan milestone—and one made possible by the dedication of people living with ALS, families, caregivers, clinicians, researchers, and advocates who have shared their experiences with Congress and demonstrated why continued action is so important. While House passage is a significant achievement, additional work remains before the bill can become law.
The Senate will now consider the legislation. Continued engagement from the ALS community will help reinforce the urgency of passing the bill before the current authorization expires. You can help keep the momentum going by asking your Senators to support the ACT for ALS Reauthorization Act. Click here to take action today.
Together, We End ALS®
